Program Curriculum 

Our pharmacy residency program provides a strong foundation for residents to build their clinical skills at training sites that value inter-professional collaboration and medical education. Residents will participate in providing care to a diverse population of patients and addressing the healthcare needs of the Central Valley. 

Required learning experiences are scheduled at each resident’s respective home-based site while elective learning experiences are available to all residents at both sites. Each rotation’s duration is 4-6 weeks. 

Learning Experiences

Required Rotations

• Hospital Operations I/II
• Internal Medicine
• Medicine Intensive Care Unit (MICU)
• Emergency Medicine
• Hospital Administration

Elective Rotations

• Ambulatory Care – Pharmacy Dialysis
• Medication Safety
• Clinical Informatics
• Supply Chain Management
• Quality/Risk Management
• Burn/Surgery ICU
• Neuro ICU
• Trauma Surgery ICU
• Pediatrics
• Neonatal ICU
• Infectious Diseases
• Inpatient Oncology
• Outpatient Oncology
• Women & Children’s

Longitudinal Resident Projects

• Pharmacy Education Seminar (1.0 CE accredited)
• Drug Monograph
• Research
• Hospital Operations Staffing

Additional Resident Opportunities

• Teaching Certificate
• Basic Life Support (BLS) Training & Certification
• Advanced Cardiac Life Support (ACLS) Training & Certification
• Pediatric Advanced Life Support (PALS) Training & Certification

Previously Completed Longitudinal Resident Projects

Pharmacy Education Seminars (1.0 CE accredited)

• Management of Immune-Checkpoint Inhibitor-Related Toxicities
• Discrepancies & Diversions in Automated Dispensing Cabinets: Pharmacy Law Overview
• Pharmacologic Management of Spinal (Cord) Injuries
• Dosing Strategies of Phenobarbital in Alcohol Withdrawal Syndrome
• Pharmacy Department – Quality Assurance Review of Vancomycin 2025

Drug Monographs

• Aztreonam-avibactam (Emblaveo)
• DaxibotulinumtoxinA-lanm (Daxxify)
• Poly-L-lactic acid (PLLA) (Sculptra)
• Glofitamab-gxbm (Columvi)

Research

• Evaluating the Outcomes of Phenobarbital versus Lorazepam among Patients with Severe Alcohol Withdrawal Symptoms in the ICU
• Efficacy and Safety of Fixed Versus Weight-Based Factor Eight Inhibitor Bypassing Activity (FEIBA) for Apixaban or Rivaroxaban Associated Intracranial Hemorrhage
• Evaluating prescribing practices of rivaroxaban and apixaban for the treatment of venous thromboembolism among patients with renal dysfunction
• Implementing a Standardized Oral Chemotherapy Management Protocol in the Inpatient Setting